In early February 2026, Haemonetics Corporation reported third-quarter results that exceeded Wall Street expectations and raised its full-year 2026 guidance, projecting first-quarter revenue of US$300 million to US$310 million and full-year revenue of US$1.22 billion to US$1.26 billion. The company’s outlook highlighted particularly strong contributions from its plasma and Blood Management Technologies businesses, alongside higher-margin products and ongoing expansion in its Hospital unit…Read More
Why Haemonetics (HAE) Raised 2026 Guidance After Strong Plasma And Tech Results And What It Signals
